Trial Profile
A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Angiocal (PRS-050-PEG40) in Patients With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2016
Price :
$35
*
At a glance
- Drugs PRS 050 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pieris
- 09 May 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003662).
- 15 Nov 2011 Results were presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, according to a Pieris media release. Results were also reported in the media release.
- 19 Oct 2011 Results will be presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, according to a Pieris media release.